Skip to main content
SpringerLink
Log in

Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study

  • Original Research Article
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Background

Pazopanib is the only tyrosine kinase inhibitor approved for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy, but there have been limited real-world data on pazopanib for the treatment of advanced STS.

Objective

We aimed to evaluate clinical outcomes of pazopanib in patients with multiple histologic STS types in real-world settings.

Patients and Methods

We retrospectively analyzed clinical data of Korean patients with advanced STS treated with pazopanib between 2008 and 2019. Outcomes of interest included treatment response, survival according to histologic subtypes, and adverse events.

Results

The analysis included 347 STS patients. The disease control rate for all pazopanib-treated patients was 54.8% (95% confidence interval (CI) 49.5–60.0); 54 patients (15.6%) achieved a partial response and 136 (39.2%) had stable disease. Patients with alveolar soft-part sarcoma (ASPS; 90%), solitary fibrous tumor (SFT; 88.2%), synovial sarcoma (66.7%), leiomyosarcoma (61.1%), and undifferentiated pleomorphic sarcoma (59.6%) showed higher disease control rates than those with other STS subtypes. Overall, median progression-free survival (PFS) and overall survival (OS) were 5.3 months (95% CI 4.5–6.0) and 12 months (95% CI 10–14), respectively. Noticeable survival outcomes occurred in patients with ASPS and SFT, with a median PFS of 24.5 (95% CI 2.5–30.0) and 13.0 (95% CI 3.0–21.3) months, respectively. The median OS of patients with ASPS and SFT was 48 (95% CI 17–52) and 32 (95% CI 19–66) months, respectively. Adverse drug reactions occurred in 170 patients (49.0%) but were not life-threatening.

Conclusions

This real-world data analysis showed acceptable efficacy and tolerability of pazopanib in patients pretreated with cytotoxic chemotherapy for advanced STS, with favorable treatment outcomes for ASPS and SFT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin Proc. 2007;82(11):1409–32.

    Article  CAS  PubMed  Google Scholar 

  2. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701–11.

    Article  CAS  PubMed  Google Scholar 

  3. Kim HS, Nam CM, Jang SY, Choi SK, Han M, Kim S, et al. Characteristics and treatment patterns of patients with advanced soft tissue sarcoma in Korea. Cancer Res Treat. 2019;51(4):1380–91.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.

    Article  CAS  PubMed  Google Scholar 

  5. Lee DY, Staddon AP, Shabason JE, Sebro R. Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development. Cancer Med. 2019;8(2):585–92.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sleijfer S, Quali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72–83.

    Article  CAS  PubMed  Google Scholar 

  7. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.

    Article  PubMed  Google Scholar 

  8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  PubMed  Google Scholar 

  9. Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015;15:154.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nakamura T, Matsumine A, Kawai A, Araki N, Goto T, Yonemoto T, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–16.

    Article  CAS  PubMed  Google Scholar 

  11. Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, et al. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. Acta Oncol. 2017;56(12):1769–75.

    Article  CAS  PubMed  Google Scholar 

  12. Kim JH, Park HS, Heo SJ, Kim SK, Han JW, Shin KH, et al. Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma. Oncology. 2019;96(2):59–69.

    Article  CAS  PubMed  Google Scholar 

  13. Jaber OI, Kirby PA. Alveolar soft part sarcoma. Arch Pathol Lab Med. 2015;139(11):1459–62.

    Article  CAS  PubMed  Google Scholar 

  14. Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013;31(18):2296–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22(7):1682–90.

    Article  CAS  PubMed  Google Scholar 

  16. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist. 2018;23(1):62–70.

    Article  CAS  PubMed  Google Scholar 

  17. Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, et al. A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma. Oncologist. 2019;24(1):20–e29.

    Article  CAS  PubMed  Google Scholar 

  18. Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019;20(7):1023–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Paoluzzi L, Maki RG. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review. JAMA Oncol. 2019;5(2):254–60.

    Article  PubMed  Google Scholar 

  20. Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer. 2009;9:22.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Goodwin ML, Jin H, Straessler K, Smith-Fry K, Zhu JF, Monument MJ, et al. Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. Cancer Cell. 2014;26(6):851–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol. 2009;21(4):327–31.

    Article  PubMed  Google Scholar 

  23. Levard A, Derbel O, Méeus P, Ranchère D, Ray-Coquard I, Blay JY, et al. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. BMC Cancer. 2013;13:109.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, et al. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res. 2013;3(1):7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23(12):3171–9.

    Article  CAS  PubMed  Google Scholar 

  26. Maruzzo M, Martin-Liberal J, Messiou C, Miah A, Thway K, Alvarado R, et al. Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. Clin Sarcoma Res. 2015;5:5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939–47.

    Article  CAS  PubMed  Google Scholar 

  28. Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(1):134–44.

    Article  CAS  PubMed  Google Scholar 

  29. Schöffski P, Cornillie J, Wozniak A, Li H, Hompes D. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat. 2014;37(6):355–62.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Chung Ryul Oh, Jung Yong Hong, and Jee Hung Kim contributed equally to this study.

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

    Chung Ryul Oh, Tae Won Kim, Jin-Hee Ahn & Jeong Eun Kim

  2. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Jung Yong Hong

  3. Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

    Jee Hung Kim

  4. Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

    Ji Sung Lee

  5. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

    Jee Hung Kim & Hyo Song Kim

Authors
  1. Chung Ryul Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jung Yong Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jee Hung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji Sung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyo Song Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tae Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin-Hee Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jeong Eun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept: Jeong Eun Kim and Tae Won Kim. Study design: Jeong Eun Kim. Data acquisition: Jeong Eun Kim, Jung Yong Hong, Jee Hung Kim, Hyo Song Kim, and Jin-Hee Ahn. Quality control of the data and algorithms: Jeong Eun Kim. Data analysis and interpretation: Jeong Eun Kim, Ji Sung Lee, and Chung Ryul Oh. Statistical analysis: Ji Sung Lee. Article preparation: Chung Ryul Oh and Jeong Eun Kim. Article editing: Chung Ryul Oh. Article review: Jeong Eun Kim, Jung Yong Hong, Jee Hung Kim, and Hyo Song Kim.

Corresponding author

Correspondence to Jeong Eun Kim.

Ethics declarations

Funding

This work was funded by a 2017 cancer research support project from the Korea Foundation for Cancer Research (CB-2017-B-2), and was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number HI18C2383).

Conflict of interest

Chung Ryul Oh, Jung Yong Hong, Jee Hung Kim, Ji Sung Lee, Hyo Song Kim, Tae Won Kim, Jin-Hee Ahn, and Jeong Eun Kim declare they have no conflicts of interest that might be relevant to the contents of this manuscript.

Consent for publication

The authors declare that the manuscript has not been published previously, in whole or in part, and is not under consideration for publication elsewhere. All authors have approved the manuscript and consent to its publication.

Ethics approval

This study was approved by the Asan Medical Center Institutional Review Board (IRB No. 2017-1098).

Availability of data and material

The data contain potentially identifiable patient information and cannot be shared publicly due to ethical and legal restrictions.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 234 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oh, C.R., Hong, J.Y., Kim, J.H. et al. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. Targ Oncol 15, 485–493 (2020). https://doi.org/10.1007/s11523-020-00731-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-020-00731-z

Search

Navigation